Jeff Reeves

Jeff Reeves

Jeff Reeves is a financial commentator with almost two decades of newsroom and markets experience, including a stint as an editor for the New York Times Co. He has been lead writer and editor for InvestorPlace.com since the beginning of 2010.  

Jeff’s work has appeared in numerous finance publications and broadcast outlets, including The Wall Street Journal network, CNBC, TheStreet.com, Fox Business Channel, USA Today and a host of others.

View some of his TV appearances on YouTube, or check out his writing links below.

Jeff has also penned an eBook, The Frugal Investor’s Guide to Finding Great Stocks: 11 Free Resources to Help Beginners Identify Fantastic Investments.

Write Jeff at editor@investorplace.com, or follow him on Twitter @JeffReevesIP.

Recent Articles

The ONLY 5 Investing Rules You Need to Follow

By Jeff Reeves

It seems every financial adviser has a list of 10, or even 25, rules investors should follow. But when you cut out all the fat, there's only five you need.

Americans Are Getting Dangerous and Desperate With Their Nest Eggs

By Jeff Reeves

Many Americans are getting dangerous and desperate with their savings, leaving retirement largely in limbo. Don't be one of them.

How Amazon.com Will Kill Costco

By Jeff Reeves

If you can find it at Costco, chances are you can find it at Amazon. Here's why the online site will be the big-box retailer of the future -- and KO Costco.

10 Buffett Dividend Stocks Paying 3% or More

By Jeff Reeves

For lovers of Warren Buffett and dividends, this is the perfect storm -- a list of some of Buffett's portfolio picks that boast high yields.

7 Stocks Under $5 Worth Pursuing

By Jeff Reeves

After combing through the market to find potential investments that come at a cheap share price, here are seven that are worth pursuing.

Coca-Cola Is Starting to Sweat

By Jeff Reeves

Rising costs weighed on Coca-Cola's bottom line for Q2, and while KO still looks good down the road, short-term headwinds shouldn't be ignored.

9 Biotech Buyout Players to Watch

By Jeff Reeves

The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.

5 Stocks Over $300 and Worth Every Penny

By Jeff Reeves

Investors are often drawn to low-priced stocks, but expensive stock picks can sometimes be worth the price. Here are five high-priced companies to consider.

Swing for the Fences With These 5 Biotech Stocks

By Jeff Reeves

If you're prepared for the very high stakes and high risks of biotech investing, these five biotech stocks might be worth your while.

Beware of Penny Stock Scam Artists

By Jeff Reeves

Penny stocks and microcaps are attractive to some investors because of the big profit potential. But they also are a playground for crooks.

Load More